Harvard Bioscience Inc. Common Stock (HBIO)

About HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other…

Sector

Industrials

Industry

Biotechnology: Laboratory Analytical Instruments

Employees

316

Website

www.harvardbioscience.com

Fundamentals

1-day range

$6.51$6.7

Market cap

$27.92M

P/E (trailing)

—

P/E (forward)

10.32

EPS (trailing)

$-2.30

Dividend yield

—

Beta

—

Avg. volume

19.6K

Forecasts

1 analyst ratings

Harvard Bioscience Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• HBIO

  Harvard Bioscience Inc. Common Stock

  $7.97

  ▲ 0.82%
  Market cap $27.92MP/E —
  $3.8$9.4
• PRPO

  Precipio Inc. Common Stock

  $28.85

  ▼ 1.50%
  Market cap $41.93MP/E —
  $14.28$33.63
• BNGO

  Bionano Genomics Inc. Common Stock

  $1.19

  ▼ 1.65%
  Market cap $12.62MP/E —
  $1$5.5
• CIRC

  Circle8 Group Inc. Common Stock

  $0.7246

  ▲ 2.34%
  Market cap $70.73MP/E —
  $0.4773$0.98
• RPID

  Rapid Micro Biosystems Inc. Class A Common Stock

  $1.56

  ▼ 3.11%
  Market cap $96.03MP/E —
  $1.52$4.94
• NAUT

  Nautilus Biotechnology Inc. Common Stock

  $0.8828

  ▼ 2.35%
  Market cap $112.76MP/E —
  $0.62$4.31
• SEER

  Seer Inc. Class A Common Stock

  $1.99

  ▼ 1.00%
  Market cap $120.41MP/E —

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5
  Benzinga · 8/12/2026
• Harvard Bioscience, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/12/2026
• Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/11/2026
• Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est.
  Benzinga · 8/11/2026
• Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est
  Benzinga · 8/11/2026
• Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M Estimate
  Benzinga · 8/11/2026

• Katherine A. Eade · June 9, 2026 · Grant

  16.6K
• William Snider · June 9, 2026 · Grant

  16.6K
• Stephen J. Denelsky · June 9, 2026 · Grant

  16.6K
• Robert E. Gagnon · June 9, 2026 · Grant

  16.6K
• Seth Benjamin Benson · June 9, 2026 · Grant

  16.6K
• Mark T. Frost · March 20, 2026 · Grant

  30.0K
• John D. Duke · March 20, 2026 · Grant

  75.0K
• William Snider · March 17, 2026 · Buy

  8.5K @ $4.85
• Stephen J. Denelsky · March 17, 2026 · Buy

  10.0K @ $4.87
• Mark T. Frost · March 16, 2026 · Buy

  5.0K @ $5
• William Snider · March 16, 2026 · Buy

  12.5K @ $4.99
• John D. Duke · March 16, 2026 · Buy

  5.0K @ $5.01

Institutional Ownership

March 31, 2026

Total shares held

1.32M

Total value held

$5.54M

Institutional holders

30